https://scholars.lib.ntu.edu.tw/handle/123456789/543856
標題: | Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer | 作者: | Chung S.-D. SHIH-PING LIU Lin H.-C. Wang L.-H. |
公開日期: | 2014 | 出版社: | Public Library of Science | 卷: | 9 | 期: | 6 | 起(迄)頁: | e101254 | 來源出版物: | PLoS ONE | 摘要: | Background: This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. Methods: We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period. Results: Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89-9.64) per 100 person-years and 2.14 (95% CI: 1.31-3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p<0.002). After adjusting for age, monthly income, and the Charlson Comorbidities Index score, PC patients who received treatment with GnRH agonists were more likely to have been hospitalized for pneumonia during the 1-year follow-up period than PC patients who did not receive treatment with GnRH agonists (hazard ratio: 1.92, 95% CI: 1.10-3.36). Conclusions: PC patients who received treatment with GnRH agonists had an increased risk of pneumonia. ? 2014 Chung et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903388898&doi=10.1371%2fjournal.pone.0101254&partnerID=40&md5=cb92240719292501dd4bfa997f258853 https://scholars.lib.ntu.edu.tw/handle/123456789/543856 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0101254 | SDG/關鍵字: | gonadorelin agonist; antineoplastic agent; gonadorelin; aged; article; Charlson Comorbidity Index; cohort analysis; disease free survival; follow up; hospitalization; human; ICD-9-CM; incidence; major clinical study; male; patient monitoring; pneumonia; proportional hazards model; prostate cancer; retrospective study; risk assessment; agonists; controlled clinical trial; controlled study; pneumonia; Prostatic Neoplasms; risk factor; very elderly; Aged; Aged, 80 and over; Antineoplastic Agents; Gonadotropin-Releasing Hormone; Humans; Male; Pneumonia; Prostatic Neoplasms; Risk Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。